UNDERSTANDING REGARDING
ARTICLE 2 OF ANNEX 26-A ON TRANSPARENCY AND PROCEDURAL FAIRNESS
FOR PHARMACEUTICAL PRODUCTS AND MEDICAL DEVICES

February 4, 2016

The Governments of the United States of America and the Republic of Peru (individually a
“Party” and collectively the “Parties”) have reached the following understanding concerning
Annex 26-A on Transparency and Procedural Fairness for Pharmaceutical Products and
Medical Devices contained in Chapter 26 (Transparency and Anti-Corruption) of the Trans-
Pacific Partnership Agreement signed this day:

The Parties recognize that with regard to Article 2 (Principles) of Annex 26-A, it is
understood that “high-quality healthcare” does not refer to specific final outcomes in
a Party’s healthcare system, including the selection of specific pharmaceutical
products.

FOR THE GOVERNMENT OF THE
UNITED STATES OF AMERICA:  FOR THE GOVERNMENT OF THE

Michael From

Alvaro Segovia